Resolvins RvD1 and 17R RvD1 alleviate signs of inflammation in a rat model of endometriosis
RvD1 and 17(R)-RvD1 reduced cyst vascular permeability and associated vaginal hyperalgesia in rats with surgically-induced endometriosis suggesting that further investigation of therapeutic anti-inflammatory potentials of resolvins can be considered.
Natalia Dmitrieva, Ph.D., Gregory Suess, B.S., Russell Shirley, B.S.
Volume 102, Issue 4, Pages 1191-1197
To study the effects of two resolvins of D series, RvD1 and 17(R)-RvD1, on inflammatory signs associated with endometriosis (ENDO).
In vivo research study.
Female Sprague-Dawley rats.
Intravenous or intraperitoneal injections of RvD1 (300 ng/kg) or 17(R)-RvD1 (300 and 900 ng/kg) in rats with surgically induced ENDO.
Main Outcome Measure(s):
Vascular permeability of ectopic endometrial growths was assessed by Evans Blue extravasation; vaginal hyperalgesia was assessed with telemetered visceromotor response.
Both resolvins, but not vehicle, significantly decreased vascular permeability in ectopic endometrial tissue. 17(R)-RvD1 also significantly alleviated severity of vaginal hyperalgesia.
Our results suggest that RvD1 and 17(R)-RvD1 can be considered for further investigation of their therapeutic potential for treating ENDO.